Latest California Healthline Stories
Klobuchar Wants To Stop ‘Pay-For-Delay’ Deals That Keep Drug Prices High
It’s as shady as it sounds.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Mulvaney: Trump Brought Down Drug Prices For The First Time In 50 Years
It’s “within spitting distance of something that’s true,” said one health economist. But our fact check found it wasn’t quite there.
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
Can Someone Tell Me What A PBM Does?
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Doughnut Hole Is Gone, But Medicare’s Uncapped Drug Costs Still Bite Into Budgets
Beneficiaries pay 25 percent of the price of their brand-name drugs until they reach $5,100 in out-of-pocket costs. After that, their obligation drops to 5 percent. But it never disappears.
Analysis: Why Americans Shouldn’t Feel Grateful For $137 Insulin
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
Must-Reads Of The Week (Some Flying Below The Radar)
Executive editor Damon Darlin takes a spin as host of “The Friday Breeze,” whirling through a week of health care news so you don’t have to.